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ABSTRACT

In 2014, the Food and Drug Administration approved naltrexone
HCl/bupropion HCl, a combination of an antidepressant and an opioid antagonist
for chronic weight management therapy. Concurrent use of antidepressants and
opioids has the potential to cause drug interactions involving serotonin
syndrome. Our primary objective is to identify cases of serotonin syndrome
and/or opioid withdrawal after initiation of naltrexone HCl/bupropion HCl. Our
secondary objective is to assess which specific opioids are more likely to cause a
drug interaction with naltrexone HCl/bupropion HCl. We performed an
observational study by reviewing cases in the RADARS® database from January
2014 through December 2018. The cases considered must have taken their first
iv

dose of naltrexone HCl/bupropion HCl with concomitant use of an opioid, and
met the inclusion criteria. Cases were determined to involve serotonin syndrome
and/or opioid withdrawal using Hunter’s Serotonin Toxicity Criteria and the
Clinical Opioid Withdrawal Scale. The primary outcome measures were total
number of cases with at least a moderate outcome, total number of cases
determined to experience serotonin syndrome and/or opioid withdrawal and total
number of cases to experience serotonin syndrome and/or withdrawal with at
least a moderate outcome. The secondary outcome measures included the
frequency of different opioids involved, benzodiazepine administration, and
supportive care with either mechanical ventilation or intubation. Thirty-three
cases in RADARS® met inclusion criteria, and 23 cases contained results for
medical outcome. The 23 cases followed to medical outcome resulted in two
major effects, 14 moderate effects and seven minor effects. Sixteen out of 23
cases (70%) had at least a moderate outcome. Seventeen out of 23 cases
(74.0%) experienced serotonin syndrome and/or withdrawal. Overall, 13 out of
17 cases (76.5%) experienced serotonin syndrome and/or withdrawal and
resulted in at least a moderate outcome. This study suggests occurrence of a
drug interaction in the form of serotonin syndrome and/or opioid withdrawal with
at least a moderate outcome after the first dose of naltrexone HCl/bupropion HCl
while on opioid therapy.
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Background
In 2015-2016, the prevalence of obesity in U.S. adults was 39.8%
according to the CDC.1 The National Health and Nutrition Examination Surveys,
from 2005-2010 reported 43.2% of obese adults also suffered from depression
as compared to 33% who did not.2 In 2014, a study by Miller et al. showed 15%
of patients with chronic pain also suffered from depressive disorder. Of the
patients with chronic pain, 16% filled an opioid alone and 28% filled both a
nonopioid and opioid as chronic pain management therapy. The most common
nonopioid medications used for pain management were non-steroidal antiinflammatory drugs (NSAIDs) and antidepressants.3 These percentages show
that antidepressant medications are likely used alone or concurrently with opioids
by patients who are obese or have chronic pain. Naltrexone HCl/bupropion HCl
is a chronic weight management therapy consisting of an opioid antagonist and
antidepressant.4 Naltrexone HCl/bupropion HCl, used by over 800,000 patients
in the U.S. is the most prescribed medication for weight loss.5 The medication
was approved for adults in 2014; it was indicated for patients with a body mass
index of 30 kg/m2 or greater or 27 kg/m2 or greater plus at least one of the
following: hypertension, type 2 diabetes, or dyslipidemia.4 Since this drug has
only been on the market for four years, there are no significant data published on
adverse effects. In the FDA approval process, adverse effects are a critical
aspect. The package insert clearly states the potential for drug interactions and
the risk of experiencing opioid withdrawal while taking naltrexone HCl/bupropion
HCl with concomitant opioid use; however, it does not mention the risk for

1

serotonin syndrome. It is important to investigate the occurrence and medical
outcome of this interaction.
Serotonin, or 5-hydroxytryptamine, is a neurotransmitter that can act both
centrally and peripherally; it is released from neurons in various regions of the
brain and the enterochromaffin cells of the gastrointestinal tract. Serotonin is
released from the lower pons and medulla, controlling nociception, wakefulness,
thermoregulation, attention, emesis, appetite, affective behavior, and motor
tone.6,7 Peripherally, it stimulates vasoconstriction, uterine contraction,
bronchoconstriction, gastrointestinal motility, and platelet aggregation. 7
Serotonin syndrome is known to cause a triad of signs and symptoms involving
altered mental status, autonomic hyperactivity, and neuromuscular abnormalities
with variable severity.6 The diagnosis includes evaluation of medical history,
physical and neurological exam, and the patient’s list of medications taken within
the last two months. Due to a plethora of signs and symptoms and the range of
severity in clinical effects, multiple attempts have been made to develop
diagnostic criteria. Sternbach originally derived his criteria in 1991 from 10 case
reports and two case series.7 Patients met this criterion by showing three of the
ten common clinical effects, along with use or dose increase of a serotonergic
agent, and absence of a neuroleptic agent.7 Radomski later reviewed 24 cases
from 1991 to 1995 and classified the cases into a mild state of serotonin related
symptoms, serotonin syndrome, or a toxic serotonergic state.8 Shortly after, he
Hunter group formulated a decision rule criterion by univariate and multivariate
analysis of a dataset of selective serotonin reuptake inhibitor (SSRI)-alone
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overdoses and a test dataset of all serotonergic medication overdoses from 1987
to 2002.9 Currently, Hunter’s Criteria is the preferred method for diagnosis.
Table 1 shows Hunter’s Criteria.9
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Table 1
Hunter Serotonin Toxicity Criteria: Decision Rules
In the presence of a serotonergic agent: serotonin toxicity occurs
1. IF spontaneous clonus = yes
2. OR IF inducible clonus = yes AND agitation = yes OR diaphoresis =
yes
3. OR IF ocular clonus = yes AND agitation = yes OR diaphoresis = yes
4. OR IF tremor = yes AND hyperreflexia = yes
5. OR IF hypertonia = yes AND temperature > 38˚ C AND ocular clonus =
yes OR inducible clonus
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter
Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for
serotonin toxicity. QJM. 2003 Sep;96(9):635-42
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Serotonin syndrome is a predictable manifestation that 85% of physicians
are unaware of or tend to overlook.10,11 It may occur after therapeutic use,
increased dose, or overdose of a single serotonergic agent, after concomitant
use of multiple serotonergic agents, or by complex drug interactions triggering
various mechanisms of serotonergic stimulation.7 It can be caused by an
increase in release of serotonin, an increase in the synthesis of serotonin, direct
receptor stimulation, inhibition of serotonin reuptake, or decreased
metabolism.7,12,13 There are 7 types of serotonin receptors (5-HT1 to 5-HT7) with
the main subtypes involved in serotonin toxicity being 5-HT1A and 5-HT2A.13,11
Along with the main mechanisms leading to excess serotonergic excitation, there
are pharmacogenomic factors that may predispose individuals to serotonin
syndrome including: variants of isoforms CYP2D6 and CYP3A4, hypersensitivity
from spliced gene variants, and allele polymorphisms.14 Inhibition of
norepinephrine reuptake, blockage of NMDA and GABA, and antagonism at 5HT3 have also been associated as indirect mechanisms of excess serotonin in
animal models.13
Antidepressants are the most common medication involved in serotonin
cases. Of the various combinations of drugs that result in pharmacodynamic
interactions, serotonin reuptake inhibitors and opioids are the most common
culprit to contribute to this syndrome.15 Selective serotonin reuptake inhibitors
(SSRIs) such as citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline, and
paroxetine bind to serotonin reuptake transporters, prevent reuptake in the
synaptic cleft, and inhibit CYP2D6 pathways. 6 Serotonin and norepinephrine
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reuptake inhibitors (SNRIs), like venlafaxine, also prevent reuptake.16 Tricyclic
antidepressants (TCAs) with a tertiary amine group, such as amitriptyline,
imipramine, and clomipramine strongly block serotonin and norepinephrine
reuptake and desensitize 5-HT, making the tertiary amine TCAs more prone to
cause serotonin syndrome.17 Monoamine oxidase inhibitors (MAOIs) inhibit
serotonin metabolism.18 The mechanism of serotonin syndrome from bupropion
is less clear.
Naltrexone HCl/bupropion HCl is a combination of a competitive opioid
antagonist and an amino ketone antidepressant. Naltrexone, which binds to mu,
kappa, and delta opioid receptors, has a great affinity for opioid receptors and
may prevent or displace opioid agonists from binding to the receptor. Bupropion
selectively inhibits neuronal uptake of dopamine and norepinephrine with indirect
effects on serotonin receptors. Bupropion and its active metabolite are both
inhibitors of CYP2D6, which may affect the metabolism of other drugs in the
body. Bupropion inhibits catecholamine reuptake activity. In rats, studies have
shown significant firing activity of serotonergic and noradrenergic neurons after
continuous administration of 30 mg/kg bupropion.19 Although the serotonergic
activity of bupropion may not be considered a direct mechanism, its inhibition of
CYP2D6 plays an indirect role in serotonin toxicity. Bupropion and its main
metabolite, hydroxybupropion, both inhibit this isoenzyme pathway leading to
increased levels of other drugs, such as SSRIs, TCAs and some opioids.20,14,21
As of March 2019, there are at least 12 published cases of serotonin syndrome
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involving bupropion (Table 2).12,21-31 Two reports were caused by bupropion
alone and four involved concurrent opioid use.22,28,23,25,27,30
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Table 2
Cases of Serotonin Syndrome Involving Bupropion
Medications
Bupropion

Age/Sex Outcome
Reference
15 M
Major
Thorpe, 2010

Bupropion, ondansetron,
paroxetine, duloxetine

68 F

Bupropion, tramadol, trazodone,
oxycodone

62 M

Moderate Falls, 2014

Bupropion, trazodone, quetiapine

70 F

Moderate Cheng, 2015

Bupropion, sertraline

62 F

Moderate Munhoz, 2004

Bupropion, tramadol, citalopram

62 M

Moderate Shahani, 2012

Bupropion, fluoxetine, trazodone,
olanzapine, risperidone,

24 M

Moderate Little, 2018

Bupropion, fluoxetine, olanzapine,
methadone

53 F

Bupropion

43 M

Bupropion, sertraline, trazodone,
linezolid, lithium

45 M

Bupropion, duloxetine,
cyclobenzaprine, oxycodone

53 M

Bupropion, paroxetine, atomoxetine

55 M
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Major

Major

Gollapudy, 2012

Dvir, 2007

Moderate Szala;y, 2008
Major

Lavery, 2001

Moderate Keegan, 2006

Major

Muzky, 2010

The phenylpiperidine derivatives and synthetic piperidine opioids are
considered to have weak serotonergic activity via serotonin reuptake inhibition
and increased intrasynaptic release through gamma amino butyric acid (GABA)
inhibition. This class includes meperidine, tramadol, methadone, fentanyl,
dextromethorphan, tapentadol, and propoxyphene.12,32 The phenanthrene
morphine analogs are not considered to be serotonin reuptake inhibitors, but may
increase intrasynaptic serotonin levels indirectly; they include morphine,
oxycodone, hydromorphone, oxymorphone, and buprenorphine. 13 In any case,
each drug possesses unique characteristics that may promote serotonin
stimulation (Table 3). In an in vitro study of human transporter-transfected
HEK293 cells, dextromethorphan inhibited SERT (the monoamine transporter of
5-HT) at the same degree as fluoxetine, methadone, and meperidine to a slightly
less degree, and tramadol, tapentadol and O-desmethyltramadol (the M1
metabolite of tramadol) weakly at therapeutic concentrations. The only opioid
that possessed relevant binding affinity for 5-HT1A was fentanyl; however,
methadone, meperidine, and fentanyl showed relevant binding for 5-HT2A (Table
3).33 According to a literature review in 2016, tramadol, meperidine and
methadone are the most common opioids involved in serotonin syndrome. 34,35
Tramadol is a partial opioid agonist and substrate of CYP2D6. It has a more
potent active metabolite that binds to the mu opioid receptor, and is a substrate
of CYP3A4.14 Tramadol inhibits neurotransmitter reuptake and has been
associated with serotonin syndrome when used with fluoxetine, citalopram,
sertraline, escitalopram, paroxetine, venlafaxine, mirtazapine, bupropion,
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oxycodone, and trazodone.20,14 Tramadol has also been reported as the most
frequent opioid involved in serotonin syndrome and serotonergic fatality. 36
Meperidine is a mu and kappa opioid agonist and a substrate of CYP2B6,
with an active metabolite normeperidine. It also inhibits serotonin reuptake and
has 5-HT2A agonism. It has been associated with serotonin syndrome, alone or
with another contributing agent, such as chlomipramine, phenelzine, fluoxetine
and citalopram.20,36
Methadone, a synthetic opioid and a racemic mixture of levomethadone and
dextromethadone, is slowly metabolized by enzymes CYP3A4, CYP2B6, and
CYP2D6, and acts as a substrate of P-glycoprotein. Levomethadone is an
inhibitor of NMDA.20 Cases of methadone causing serotonin toxicity have been
reported with co-administration of tramadol, paroxetine, citalopram, fluoxetine,
phenelzine, fentanyl, duloxetine, venlafaxine, and ciprofloxacin. 34,36
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Table 3
Opioid Characteristics
Drug

Morphine

Mechanism of
serotonergic
activity
Inhibits serotonin
reuptake
Increased
serotonin release
Inhibits serotonin
reuptake, Inhibits
efflux of 5-HT
Activates serotonin
receptor
Inhibits serotonin
reuptake
Increased
serotonin release
Activates serotonin
receptor
Inhibits serotonin
reuptake
Activates serotonin
receptor
Indirect

Oxycodone

Indirect

Tapentadol

Inhibits serotonin
reuptake

Dextromethorphan

Buprenorphine

Inhibits serotonin
reuptake
Increased
serotonin release
Indirect

Hydrocodone

Indirect

Hydromorphone
Oxymorphone
Bupropion

Indirect
Indirect
Indirect

Tramadol

Fentanyl

Methadone

Meperidine
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Substrate Inhibitor Receptor
agonist
activity
CYP2D6
CYP3A4

CYP3A4,
P-gp

CYP3A4,
CYP2B6,
CYP2D6
P-gp

5-HT1A
5-HT2A

CYP2D6

CYP2B6

5-HT2A

5-HT2A

CYP3A4
P-gp
CYP3A4,
CYP2D6
CYP2C9
CYP2C19
CYP2D6
CYP2D6
CYP3A4

CYP3A4
P-gp
CYP2D6
CYP3A4

CYP2D6
CYP3A4

CYP2B6
CYP3A4
CYP2C19

CYP2D6

Methods
Post-marketing surveillance for prescription opioids is available through
The Researched Abuse, Diversion, and Addiction-Related Surveillance System
(RADARS).37 This system is a subsidiary of Denver Health and Hospital
Authority, funded by subscriptions from pharmaceutical manufacturers,
government, and non-government agencies. RADARS provides a mosaic
strategy surveillance system for monitoring of newly approved drugs by collecting
product-and-geographically specific data on abuse, misuse, and diversion of
prescription drugs for research and reporting services. This system allows
RADARS to provide services such as post marketing surveillance,
epidemiological studies, advisory board participation, and advisory committee
consultation. There are 51 out of 55 poison centers in the U.S. that partner with
RADARS to provide weekly detailed exposure cases involving prescription
opioids. RADARS methods have been published previously.38 We investigated
cases of naltrexone HCl/bupropion HCl taken along with an opioid, reported to
RADARS by participating poison centers. Poison center cases in the RADARS’
database include de-identified case notes as well as data captured in
standardized fields used by the National Poison Data System. 39 Field definitions
for substance and clinical effects are published by the American Association of
Poison Control Centers.39 Our database review searched for cases occurring
from January 2014 to December 2018. Eligible cases included all human
exposure cases where a prescription opioid from the RADARS list and
naltrexone HCl/bupropion HCl were included in the substance field. RADARS
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personnel identified eligible cases using the search field for prescription opioids
captured in RADARS (buprenorphine, fentanyl, hydrocodone, hydromorphone,
meperidine, methadone, morphine, oxycodone, oxymorphone, tapentadol and
tramadol) who also took their first dose of naltrexone HCl/bupropion HCl.37,39
Exclusion criteria were information cases, animal exposures, subjects under the
age of eighteen, and subjects who were pregnant or incarcerated. Each case
was assessed for case notes and clinical effects that were consistent with
published criteria for terms used in diagnosis of either opioid withdrawal or
serotonin syndrome (Appendix A).40 Clinical effects captured in the case notes
that reflected opioid withdrawal or serotonin syndrome were searched for via text
search using the terms provided in the (Appendix A) and their synonyms.
RADARS personnel collected the following information for each case: reason for
exposure: opioid formulation, name and dose, dose of naltrexone HCl/bupropion
HCl, duration of exposure, medical outcome, sex, age, exposure acuity, onset of
symptoms, generic code for other medications involved, and year. NPDS was
used to define terms used to capture demographics, reason for exposure, drugs
involved, route of administration, and medical outcome (Appendix B). RADARS
assigned unidentifiable codes for each case securely transferred the data to the
New Mexico Poison and Drug Information Center using our approved Data Use
Agreement. Two pharmacists reviewed the de-identified cases to assure there
were no discrepancies in determining who experienced serotonin syndrome
and/or opioid withdrawal by using Hunter’s Serotonin Toxicity Criteria and the
Clinical Opioid Withdrawal Scale (Appendix C).40 In the case of a discrepancy, a
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medical toxicologist would act as the third individual to review the case and make
the final diagnosis. These methods were used to collect data for our outcome
measures.
Our primary outcome measures included the following: cases with at least
a moderate outcome, cases determined to experience serotonin syndrome
and/or opioid withdrawal, and cases determined to experience serotonin
syndrome and/or opioid withdrawal with at least a moderate outcome.
Secondary measures included opioids involved, benzodiazepine treatment, and
mechanical ventilation or intubation in cases experiencing serotonin syndrome
and/or withdrawal. A potential confounder for this study is concomitant use of
any additional serotonergic agents. Additional serotonergic agents reported in
the cases will be disclosed in the results. The number of cases determined to
meet inclusion criteria will be our study size. We will use descriptive statistics to
determine results. Demographic information will include all cases that meet
inclusion criteria. As a database review, some cases will be missing data or will
be lost to follow up. The primary and secondary outcome results will not include
cases that are not followed to medical outcome. Any cases with missing data in
the following columns will not be included in the primary or secondary outcome
results: symptoms onset after naltrexone HCl/bupropion HCl, opioid involved,
naltrexone HCl/bupropion HCl dose.
Results
RADARS identified 33 cases that met inclusion criteria for this study.
Demographics for these cases include 28 females (84.9%) and five males
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(15.1%) with a mean age of 52.8 and standard deviation of 12.0. The ages
range from 26 to 73 years of age. The reported reasons for exposure are as
follows: therapeutic error-16 (48.5%), adverse drug reaction-11 (33.3%),
intentional misuse-two (6.1%), intentional abuse-two (6.1%), withdrawal-one
(3.0%) and intentional unknown-one (3.0%). For all 33 cases, medical outcomes
include four major effects, 12 moderate effects, seven minor effects, six not
followed due to minimal expected effects, three unable to follow but judged as
potentially toxic, and one determined as unrelated effects. Ten cases out of the
33 had missing data and were excluded from any results. Of those cases, none
were followed to outcome, and two were lacking data in the symptoms onset
field. The demographics of the ten excluded cases are shown in (Table 4). The
23 cases that were followed to medical outcome include four major effects, 12
moderate effects and seven minor effects. Sixteen out of 23 cases (70%) were
determined to have at least a moderate outcome. Seventeen cases out of 23
cases (74.0%) were determined to experience serotonin syndrome and/or
withdrawal. Overall, 13 out of 17 cases (76.5%) that experienced serotonin
syndrome and/or withdrawal were determined to have at least a moderate
outcome (Table 5). Thirteen out of 23 cases (56.5%) were administered
benzodiazepine therapy. Three out of 23 cases (13.0%) required either
mechanical ventilation or intubation. The following opioids were involved in the
17 cases that experienced serotonin syndrome and/or opioid withdrawal:
tramadol-six (35.3%), buprenorphine-three (17.7%), hydromorphone-two
(11.8%), morphine-two (11.8%), oxymorphone-one (5.9%), hydrocodone-one
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(5.9%), oxycodone with fentanyl-one (5.9%) and oxycodone with oxymorphoneone (5.9%). Two cases out of four cases with serotonin syndrome involved
tramadol; the remaining two cases involved either buprenorphine or
hydromorphone (Table 6). Eight cases out of 23 cases followed to medical
outcome reported use of other medications. Duloxetine and cyclobenzaprine,
known serotonergic agents, were reported in one case without serotonin
syndrome and one case with serotonin syndrome. Out of the six remaining
cases that listed other medications, three reported miscellaneous or unknown
drugs and three reported drugs without serotonergic activity. If these drugs were
taken prior to initiation of symptoms, it is possible they contributed to the
interaction.
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Table 4
Demographics of the ten excluded cases
Age

Sex

Reason

Opioid

Medical
Outcome

62

F

Therapeutic
Error

Tramadol

Not followed

>20

F

Therapeutic
Error

Oxycodone

Not followed

67

F

Therapeutic
Error

Tramadol

Not Followed

26

F

Withdrawal

Methadone

Unable to
follow

60

F

Adverse
Reaction Drug

Hydrocodone

Not followed

37

F

Adverse
Reaction Drug

Buprenorphine

Not followed

52

F

Adverse
Reaction Drug

Buprenorphine

Unrelated
effect

38

F

Adverse
Reaction Drug

Buprenorphine

Unable to
follow

F

Intentional
Misuse

F

Therapeutic
Error

56

Unknown

17

Not followed
Oxycodone

Methadone

Unable to
follow

Table 5
Cases determined to experience serotonin syndrome and/or withdrawal
that were followed to medical outcome
Medical
Opioid Involved
outcome
Major
Buprenorphine

Opioid Withdrawal

No

Mild

Hydrocodone

No

Moderate

Hydromorphone

No

Mild

Yes

Mild

Oxymorphone

No

Mild

Oxycodone/fentanyl

No

Mild

Tramadol

Yes

Mild

Morphine

No

Mild

Buprenorphine

No

Mild

Tramadol

No

Mild

Tramadol

No

Mild

Buprenorphine

Yes

Mild

Morphine

No

Mild

Oxycodone/oxymorphone No

Mild

Tramadol

No

Mild

Tramadol

No

Mild

Tramadol

Yes

Mild

Moderate Hydromorphone

Minor

Serotonin
Syndrome
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Table 6
Age

Sex

(yrs)

(M/F)

Opioid involved

Medical

Meets

outcome

Hunters

COWS

Oxycodone IR;
Unknown M

Oxymorphone ER Minor effect

No

Mild

33

F

Tramadol

Minor effect

Yes

None

39

F

Methadone

Minor effect

No

None

39

F

Buprenorphine

Moderate effect

No

Mild

40

F

Tramadol

Moderate effect

Yes

Mild

45

F

Tramadol

Minor effect

No

Mild

45

M

Hydrocodone

Major effect

No

Moderate

46

F

Tramadol

Moderate effect

No

Mild

49

F

Buprenorphine

Major effect

No

Mild

Oxycodone;
51

F

Fentanyl

Moderate effect

No

Mild

51

F

Morphine

Moderate effect

No

None

52

F

Tramadol

Minor effect

No

Mild

54

F

Morphine

Moderate effect

No

Mild

Methadone;
56

M

Hydrocodone IR,

Major effect

No

None

57

M

Tramadol

Minor effect

No

None

59

F

Morphine

Moderate effect

No

None

59

F

Tramadol

Moderate effect

No

Mild

63

F

Hydromorphone

Major effect

Yes

Mild

68

F

Buprenorphine

Moderate effect

Yes

Mild

68

M

Morphine

Moderate effect

No

Mild

69

F

Hydromorphone

Minor effect

No

None

70

F

Hydromorphone

Moderate effect

No

Mild

73

F

Oxymorphone

Moderate effect

No

Mild
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Discussion
We hypothesized that patients on chronic opioid therapy would experience
a drug interaction with their first dose of naltrexone HCl/bupropion HCl, with at
least a moderate outcome. Our study determined 17 out of 23 cases (74%)
experienced serotonin syndrome and/or withdrawal. Thirteen cases out of the 17
(76.5%) had at least a moderate medical outcome. Tramadol was the most
common opioid involved in patients who experienced serotonin syndrome and/or
withdrawal (6/17; 35.5%) and the most common opioid involved in serotonin
syndrome cases (2/4; 50%). Some cases may have resulted in a moderate or
major outcome without the presence of serotonin syndrome or opioid withdrawal
due to the terminology used in the patient’s chart limiting the diagnosis. These
results support our theory of a potential drug interaction. When naltrexone
HCl/bupropion HCl is taken within seven days of an opioid it may indirectly
enhance serotonergic activity causing excess stimulation at the 5HT-1A or 5HT2A receptors through various mechanisms. At least 12 cases of serotonin
syndrome reported in the literature involve bupropion; however, these are case
reports involving serotonin syndrome. Current literature lacks studies conducted
to determine the prevalence of serotonin syndrome given a specific medication or
patient population. In alignment with our study, previous studies report tramadol
as the most frequent opioid involved in cases of serotonin syndrome.36 As
naltrexone HCl/bupropion HCl is a widely used prescription in the United States,
it is important to be aware of the potential risks that are associated. Serotonin
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syndrome is not one of the risks mentioned in the package insert as of April
2019.
Study Limitations
The limitations of this study include small sample size, potential for
reporting bias, misclassification and confounders. This data represents passive
collection of data reported voluntarily from healthcare facilities to poison and drug
information centers which ends up in the RADARS post marketing surveillance
database. Like other retrospective studies involving the National Poison Data
System, collected data may be incomplete and include reporting bias or
misclassification. Without complete chart access, it is difficult to diagnose
serotonin syndrome or classify opioid withdrawal due to the specific terminology
used in Hunter’s Criteria and the COWS. It is less likely the terminology in the
diagnostic criteria be used in the RADARS database, since it is common for
physicians to be unaware of serotonin syndrome. Confounding variables in a
retrospective review are likely, with home or ingested medications being our main
concern. Without knowing whether the opioids were prescribed or street drugs it
is difficult to determine where the focus of awareness and education should lie.
This data likely represents an underestimation of cases resulting in serotonin
syndrome and/or opioid withdrawal when opioid therapy is not stopped seven to
ten days prior to initiation of naltrexone HCl/bupropion HCl.
Future Considerations
Ultimately, this study provides support for further investigation. RADARS
database does not contain cases of naltrexone HCl/bupropion HCl without the
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use of an opioid. In order to analyze the data further, a control group of patients
taking naltrexone HCl/bupropion HCl without opioids may be considered. A
database such as Truven or HealthFacts may enhance the study by providing
data on how many prescriptions for naltrexone HCl/bupropion HCl are written
and their coinciding healthcare visits. RADARS data only includes prescription
opioids; however, it does not necessarily tell us whether the ingested opioid was
prescribed or not. Accessing a PMP, in order to identify whether the involved
opioids were prescribed or street drugs may also benefit in order to evaluate
where additional education/counseling to healthcare providers or patients is
needed.
Conclusion
Our study suggests patients on opioid therapy may experience a drug
interaction in the form of serotonin syndrome and/or opioid withdrawal upon
initiation of naltrexone HCl/bupropion HCl. Out of 800,000 prescriptions for this
drug, we identified 33 cases that developed adverse effects after their first dose.
The true rate of drug interactions is likely higher. Future studies may incorporate
healthcare visits associated within a certain timeframe of the filled naltrexone
HCl/bupropion HCl prescription along with a control group to compare results.
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Appendix A. Clinical Effects/Clinical Notes Terms Used in Text Search
RADARS Search Terms
Clinical effects captured in RADARS that reflect opioid withdrawal include
tachycardia, hypertension, abdominal pain, vomiting, nausea, agitated/irritable,
excess secretions, diaphoresis, mydriasis, diarrhea, lacrimation, tachypnea,
tremor, dehydration, pain (not dermal), rhabdomyolysis, increased CPK.41
Clinical effects that are captured in the RADARS notes field that reflect opioid
withdrawal searched for via text search for the terms piloerection, withdrawal,
and goosebumps, yawning, rhinorrhea, perspiration, restlessness. 41
Clinical effects captured in RADARS that reflect serotonin excess include tremor,
fever, agitated/irritable, tachypnea, hypertension, rigidity, diaphoresis,
tachycardia, seizures (single, intermittent or status), renal failure, increased
creatinine, disseminated intravascular coagulation, hypotension, nystagmus,
mydriasis, excess secretions, confusion, drowsiness/lethargy, coma,
hallucinations, ataxia, dystonia, diarrhea, abdominal pain, acidosis, cytopenia,
erythema/flushing, rhabdomyolysis, increased CPK.41
Clinical effects captured in the RADARS notes field that reflect serotonin excess
will be searched for via text search for the terms (serotonin syndrome, clonus,
myoclonus, hyperreflexia, increased deep tendon reflex, opisthotonus, increased
white blood cell count, leukocytosis, thrombocytopenia, altered mental status,
mania, hypomania).41
RADARS collects the following reasons for exposure based on AAPCC
guidelines: opioid formulation, name and dose, dose of naltrexone HCl/bupropion
23

HCl, coded duration, major, minor, or moderate death, sex, age, coded acuity,
onset of symptoms, generic code for other medications ingested and year.
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Appendix B. NPDS Definitions
Medical Outcome
NPDS term
NPDS definition
No effect
The patient did not develop any signs or symptoms as a result
of the exposure.
Minor effect
The patient developed some signs or symptoms as a result of
the exposure, but they were minimally bothersome and
generally resolved rapidly with no residual disability or
disfigurement. A minor effect is often limited to the skin or
mucus membranes (e.g. self-limited gastrointestinal
symptoms, drowsiness, skin irritation, first-degree dermal burn,
sinus tachycardia without hypotension, and transient cough).
Moderate
The patient exhibited signs or symptoms as a result of the
effect
exposure that were more pronounced, more prolonged, or
more systemic in nature than minor symptoms. Usually, some
form of treatment is indicated. Symptoms were not lifethreatening, and the patient had no residual disability or
disfigurement (e.g. corneal abrasion, acid base disturbance,
high fever, disorientation, hypotension that is rapidly
responsive to treatment, and isolated brief seizures that
respond readily to treatment).
Major effect
The patient exhibited signs or symptoms as a result of the
exposure that were life-threatening or resulted in significant
residual disability or disfigurement (e.g. repeated seizures or
status epilepticus, respiratory compromise requiring intubation,
ventricular tachycardia with hypotension, cardiac or respiratory
arrest, esophageal stricture, and disseminated intravascular
coagulation).
Death
The patient died as a result of the exposure or as a direct
complication of the exposure.
National Poison Data System.(2016). NPDS Coding Users’ Manual Version 3.2. American
Association of Poison Control Centers

25

Appendix B Continued NPDS Definitions
Coding Options Reason for Exposure
Unintentional - Therapeutic error
An unintentional deviation from a proper therapeutic regimen that results in the
wrong dose, incorrect route of administration, administration to the wrong
person, or administration of the wrong substance. Includes instances in which
any type of substance (medications, herbals, non-pharmaceuticals or other
products) is substituted for a medication. Drug interactions (or drug/food
interactions) resulting from unintentional administration of drugs/foods which are
known to interact should also be included.
Unintentional - Unknown
An exposure determined to be unintentional but the exact reason is unknown
Intentional - Misuse
An exposure resulting from the intentional improper or incorrect use of a
substance for reasons other than the pursuit of a psychotropic effect.
Intentional - Abuse
An exposure resulting from the intentional improper or incorrect use of a
substance where the patient was likely attempting to gain a high, euphoric effect
or some other psychotropic effect, including recreational use of a substance for
any effect.
Intentional - Unknown
An exposure that is determined to be intentional but the specific motive is
unknown
Adverse Reaction – Drug
Unwanted effects due to an allergic, hypersensitivity, or idiosyncratic response
to the active ingredient(s), inactive ingredient(s) or excipient of a drug, chemical,
or other drug substance when the exposure involves the normal, prescribed,
labeled or recommended use of the substance
National Poison Data System.(2016). NPDS Coding Users’ Manual Version 3.2. American
Association of Poison Control Centers

26

Appendix C. Diagnostic Criteria
Hunter’s Criteria
Hunter Serotonin Toxicity Criteria: Decision Rules
In the presence of a serotonergic agent: serotonin toxicity occurs
1. IF spontaneous clonus = yes
2. OR IF inducible clonus = yes AND agitation = yes OR
diaphoresis = yes
3. OR IF ocular clonus = yes AND agitation = yes OR
diaphoresis = yes
4. OR IF tremor = yes AND hyperreflexia = yes
5. OR IF hypertonia = yes AND temperature > 38˚ C AND
ocular clonus = yes OR inducible clonus
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The
Hunter Serotonin Toxicity Criteria: simple and accurate
diagnostic decision rules for serotonin toxicity. QJM. 2003
Sep;96(9):635-42
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Appendix C Continued
Clinical Opioid Withdrawal Scale
Clinical effect Rating
Resting
0 pulse rate 80 or below
Pulse Rate
1 pulse rate 81-100
2 pulse rate 101-120
4 pulse rate greater than 120
Sweating
0 no report of chills or flushing
1 subjective report of chills or flushing
2 flushed or observable moistness on face
3 beads of sweat on brow or face
4 sweat streaming off face
Restlessness 0 able to sit still
1 reports difficulty sitting still, but is able to do so
3 frequent shifting or extraneous movements of legs
or arms
5 unable to sit still for more than a few seconds
Pupil Size
0 pupil pinned or normal size for room light
1 pupils possibly larger than normal for room light
2 pupils moderately dilated
5 pupils so dilated that only the rim of the iris visible
Bone or Joint 0 not present
Aches
1 mild diffuse discomfort
2 patient reports severe diffuse aching of joints or
muscles
4 patient is rubbing joints or muscles and is unable
to sit still because of discomfort
Runny Nose
0 not present
or Tearing
1 nasal stiffness or unusually moist eyes
2 nose running or tearing
4 nose constantly running or tears streaming down
cheeks
GI Upset
0 no GI symptoms
1 stomach cramps
2 nausea or loose stool
3 vomiting or diarrhea
5 multiple episodes of diarrhea or vomiting
Tremor
0 no tremor
1 tremor can be felt, but not observed
2 slight tremor observable
4 gross tremor or muscle twitching
Yawning
0 no yawning
1 yawning once or twice during assessment
2 yawning three or more times during assessment
4 yawning several times/minute
28

Score

Anxiety or
Irritability

Gooseflesh
Skin

Total Score

0 none
1 patient reports increasing irritability or anxiousness
2 patient obviously irritable anxious
4 patient so irritable or anxious that participation in
the assessment is difficult
0 skin smooth
3 piloerection of skin can be felt or hairs standing up
on arms
5 prominent piloerection
5-12=mild; 13-24=moderate; 25-36=moderately
severe; more than 36=severe withdrawal
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Appendix D. Abbreviations or Acronyms

AAPCC: American Association of Poison Control Centers
CDC: Center for Disease Control
COWS: Clinical Opioid Withdrawal Scale
CPK: creatinine phosphokinase
CYP: Cytochrome P450
FDA: Food and Drug Administration
HCl: Hydrochloride
GABA: Gamma-Amino-Butyric Acid
MAOI: Mono Amine Oxidase Inhibitor
NMDA: N-methyl D-Aspartate
NPDS: National Poison Data System
NSAIDS: Nonsteroidal Anti-Inflammatory Drugs
PMP: Prescription Monitoring Program
RADARS: Researched Abused Diversion and Addiction Research System
SNRI: Serotonin Norepinephrine Reuptake Inhibitor
SSRI: Selective Serotonin Reuptake Inhibitor
TCA: Tricyclic Antidepressant
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